Landmark Lawsuit Filed Against SEC to Protect Future Whistleblowers

December 15, 2020

Roland M. Mathys

Trading and Pricing


Defendants: Roland M. Mathys

Default judgment against Swiss trader. The SEC found that Mathys received material non-public information about an impending acquisition of Bioverativ Inc. (NASDAQ) by Sanofi S.A. and, on the basis of that information, purchased approximately $169,000 worth of out-of-the-money Bioverativ call options prior to the public announcement, resulting in profits of approximately $5 million.

Named one of the top whistleblower practices/attorneys in the country by The New York Times, Wall Street Journal and NPR
Thank you for submitting some email to us.